NCT03653507 2026-04-17
GLOW
Astellas Pharma Inc
Phase 3 Active not recruiting
Clinical Trials
49 trialsNCT05152147 2026-04-17
HERIZON-GEA-01
Jazz Pharmaceuticals
Phase 3 Active not recruiting
NCT07431281 2026-04-13
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
AstraZeneca
Phase 3 Recruiting
NCT05568095 2026-04-02
STAR-221
Arcus Biosciences, Inc.
Phase 3 Active not recruiting
NCT03221426 2026-03-09
KEYNOTE-585
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT04882241 2026-03-06
KEYNOTE-585
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT03675737 2026-02-27
KEYNOTE-859
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT06532006 2026-02-27
A Phase â…¢ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
Shanghai Henlius Biotech
Phase 3 Recruiting
NCT03399110 2026-01-27
XELOX for 4 Months Versus 6 Months in Gastric Cancer (LOMAC)
Fudan University
Phase 3 Active not recruiting
NCT07315750 2026-01-21
A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.
RemeGen Co., Ltd.
Phase 3 Recruiting
NCT03615326 2025-12-11
MK-3475-811
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT03813784 2025-09-16
A Clinical Study To Evaluate Camrelizumab (SHR-1210) Plus Capecitabine and Oxaliplatin Followed by Sequential Treatment With Camrelizumab Plus Apatinib Mesylate in Advanced or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJ) Without Prior Systemic Therapy
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Completed
NCT02872116 2025-08-07
CheckMate649
Bristol-Myers Squibb
Phase 3 Completed
NCT05144854 2024-09-05
A Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)
Ono Pharmaceutical Co. Ltd
Phase 3 Active not recruiting
NCT03006705 2024-05-03
Study of Adjuvant ONO-4538 With Resected Gastric Cancer
Ono Pharmaceutical Co. Ltd
Phase 3 Completed
NCT01917552 2024-02-28
Adjuvant Capecitabine Versus Observation Alone in Curatively Resected Stage IB Gastric Cancer((KCSG ST14-05): CATALYSIS
Asan Medical Center
Phase 3 Recruiting
NCT01935778 2024-02-28
Compare Adjuvant Chemotherapy of Docetaxel/Capecitabine/Oxliplatin Versus Capecitabine/Oxaliplatin in Advanced Gastric Cancer at Stage IIIb and IV(KCSG ST15-08): TRIUMPH
Asan Medical Center
Phase 3 Recruiting
NCT06177041 2024-02-28
M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.
FutureGen Biopharmaceutical (Beijing) Co., Ltd
Phase 3 Recruiting
NCT02494583 2023-04-13
MK-3475-062
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT03745170 2023-03-01
Efficacy and Safety Evaluation of Sintilimab or Placebo in Combination With XELOX as First Line Treatment in Patients With Gastric Cancer
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3 Completed
NCT04787354 2022-02-21
Optimal Duration of Oxaliplatin in Adjuvant XELOX for Gastric Cancer Patients (EXODOX)
Hallym University Medical Center
Phase 3 Recruiting
NCT04859582 2021-12-16
KEYNOTE-859
Merck Sharp & Dohme LLC
Phase 3 Withdrawn
NCT02395640 2021-10-26
The Comparison of XELOX and EOX in the First-line Treatment of Advanced Gastric Cancer
Fudan University
Phase 3 Completed
NCT02934464 2021-09-13
ARMANI
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 3 Unknown
NCT04997837 2021-08-10
Study of Adjuvant Chemotherapy With or Without PD-1 Inhibitors and Chemoradiotherapy in Resected pN3 Gastric (G) or GEJ Adenocarcinoma
Fudan University
Phase 3 Recruiting
NCT01774786 2020-12-30
JACOB
Hoffmann-La Roche
Phase 3 Completed
NCT02114359 2020-10-23
Chemotherapy Options for the First Line Chemotherapy in Elderly Patient With Advanced Gastric Cancer
Seoul National University Hospital
Phase 3 Completed
NCT04351867 2020-07-16
A Clinical Trial of Two Adjuvant Chemotherapy Regimens for Postoperative Gastric Cancer
Henan Cancer Hospital
Phase 3 Unknown
NCT04135781 2020-03-23
Nab-paclitaxel Combined With S-1 as Adjuvant Chemotherapy for Stage â…¢ Gastric Cancer
Zhejiang Cancer Hospital
Phase 3 Unknown
NCT01470742 2019-12-30
Trial Comparing Capecitabine Plus Oxaliplatin (XELOX) and Capecitabine (X) as First-line Chemotherapy in Elderly Patients With Advanced Gastric Cancer
Samsung Medical Center
Phase 3 Withdrawn
NCT02076594 2019-10-09
Low-Tox Vs Eox In Patients With Locally Advanced Unresectable Or Metastatic Gastric Cancer
Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente
Phase 3 Terminated
NCT03023436 2019-09-13
Cytoreductive Surgery Combined With HIPEC and Chemotherapy for Gastric Cancer With Peritoneal Metastasis
Nanfang Hospital, Southern Medical University
Phase 3 Unknown
NCT03889626 2019-03-26
The Maintenance Treatment of Apatinib/Capecitabine Versus Observation in Advanced Gastric Cancer
Fudan University
Phase 3 Unknown
NCT03598348 2018-07-26
Evaluate the Efficacy of Maintenance Treatment With Capecitabine Plus Apatinib in Advanced Gastric Cancer
Huazhong University of Science and Technology
Phase 3 Unknown
NCT03355612 2017-11-28
XELOX Plus Apatinib vs XELOX as Post-operative Chemotherapy in Locally Advanced Gastric Signet Ring Carcinoma
Tianjin Medical University Cancer Institute and Hospital
Phase 3 Unknown
NCT02289547 2017-06-14
Phase 3 Study of Xelox Followed by Maintenance Capecitabine in the Advanced Gastric Cancer
The Catholic University of Korea
Phase 3 Unknown
NCT00887822 2017-03-01
AVATAR
Hoffmann-La Roche
Phase 3 Completed
NCT01450696 2016-11-28
HELOISE
Hoffmann-La Roche
Phase 3 Terminated
NCT02560974 2016-11-02
A Study of Capecitabine (Xeloda) in Combination Chemotherapy Versus Surgery Alone in Participants With Gastric Cancer
Hoffmann-La Roche
Phase 3 Completed
NCT02563054 2016-11-02
A Study of Capecitabine (Xeloda) in Participants With Advanced or Metastatic Gastric Cancer
Hoffmann-La Roche
Phase 3 Completed
NCT02137343 2016-04-04
RILOMET-2
Amgen
Phase 3 Terminated
NCT01697072 2016-02-09
RILOMET-1
Amgen
Phase 3 Terminated
NCT00718354 2015-05-13
GASTRANOX
Thrombosis Research Institute
Phase 3 Completed
NCT01041404 2014-11-05
ToGA Study - A Study of Herceptin (Trastuzumab) in Combination With Chemotherapy Compared With Chemotherapy Alone in Patients With HER2-Positive Advanced Gastric Cancer
Hoffmann-La Roche
Phase 3 Completed
NCT01748851 2014-11-04
XELOX Versus FOLFOX for Advanced Gastric Cancer (AGC)
Dong-A University Hospital
Phase 3 Terminated
NCT00678535 2014-07-21
EXPAND
Merck KGaA, Darmstadt, Germany
Phase 3 Completed
NCT00411229 2013-02-20
CLASSIC
Sanofi
Phase 3 Completed
NCT01468389 2011-11-10
Taxanes or Platinum in Combination With Capecitabine Followed by Capecitabine Alone as First Line Treatment for Patients With Advanced Adenocarcinoma of Stomach or Esophagogastric Junction
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Phase 3 Unknown
NCT00323830 2011-11-09
Phase III Randomized Trial of Adjuvant XP Chemotherapy and XP/RT for Resected Gastric Adenocarcinoma
Samsung Medical Center
Phase 3 Completed